CLINICAL TRIALS PROFILE FOR SORIATANE
✉ Email this page to a colleague
All Clinical Trials for SORIATANE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00156247 ↗ | Acitretin and Etanercept in Psoriasis | Completed | Connetics Corp. | Phase 2 | 2005-09-01 | To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults. |
| NCT00156247 ↗ | Acitretin and Etanercept in Psoriasis | Completed | University of Medicine and Dentistry of New Jersey | Phase 2 | 2005-09-01 | To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults. |
| NCT01545284 ↗ | Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis | Completed | Tribute Pharmaceuticals | Phase 2/Phase 3 | 2012-03-01 | This pilot, phase II, 24-week study will recruit a total of 10 patients and will evaluate the efficacy and safety of acitretin in patients with severe chronic hand dermatitis . |
| NCT01545284 ↗ | Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis | Completed | Innovaderm Research Inc. | Phase 2/Phase 3 | 2012-03-01 | This pilot, phase II, 24-week study will recruit a total of 10 patients and will evaluate the efficacy and safety of acitretin in patients with severe chronic hand dermatitis . |
| NCT02050321 ↗ | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | Terminated | University of Arizona | Phase 2 | 2013-12-01 | We propose to conduct a phase 2 study to assess whether the addition of acitretin to vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC) development, a known side effect of vemurafenib therapy, in patients with advanced melanoma. Further, we seek a preliminary assessment as to whether the addition of acitretin to vemurafenib enhances the clinical efficacy of this anti-melanoma agent. |
| NCT02113904 ↗ | Clinical Trial Using Humira in Netherton Syndrome | Completed | Assistance Publique - Hôpitaux de Paris | Phase 2 | 2014-01-27 | The main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome after 3 months of treatment , with a post treatment period follow-up of 3 months. Second objectives are To evaluate the safety of Adalimumab in the context of NS To evaluate the improvement of the quality of life at 3 months To evaluate the improvement of pruritus and pain in the patients To study markers of inflammatory and allergy in NS prior and after treatment Benefit of the study An improvement by at least 20% of the cutaneous signs in these patients who suffer from a genetic incurable, chronic, painful and very afflicting disease would be of a great help for these patients. NS is a major source of social exclusion. Risks They are inherent to the risks of biotherapies, especially for an anti-TNF therapy, they comprise a risk of infection. Cutaneous infections occur mainly during infancy, and we have therefore chosen to treat patients over 4 years of age in this study. A close clinical surveillance will be set up (initially every week during the first month of treatment, then every month). This will represents a large number of visits but will provide a high level of security. Benefits/risks ratio In the absence of curative treatment for these patients with a severe genetic skin disease, the benefits/risks ration clearly appears to be in favour of an expected benefit. |
| NCT03529955 ↗ | Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis | Completed | Tulane University | Phase 2 | 2018-06-12 | With limited treatment options available for dermatomyositis, the investigators hypothesize that apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, is a safe and efficacious add-on treatment in patients with refractory cutaneous dermatomyositis. The study will investigate the efficacy, safety and toxicity of apremilast given at 30 mg twice daily to patients with refractory cutaneous dermatomyositis. Clinical response will be assessed at 1 and 3 months. Patients will also be evaluated for durability of their response for up to 6 months. Treatment will be monitored with frequent clinical visits (0, 1, 3 and 6 months) and blood tests (CBC, CMP, creatine kinase, aldolase). Treatment will be discontinued at disease progression or unacceptable adverse events. Disease progression is defined as 4 points increase in the cutaneous dermatomyositis disease area and severity index (CDASI) score, worsening of muscle disease by manual muscle testing (MMT-8) score and 5 points increase in dermatomyositis life quality index (DLQI). 5 mm skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment for gene expression profiling and confirmatory immunohistochemical stains. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SORIATANE
Condition Name
Clinical Trial Locations for SORIATANE
Trials by Country
Clinical Trial Progress for SORIATANE
Clinical Trial Phase
Clinical Trial Sponsors for SORIATANE
Sponsor Name
